Sun Pharma ko US se badi raahat mili hai! Innovative drugs par tariff ko **2 saal** ke liye postpone kar diya gaya hai. Q1 FY27 mein company ne **27%** ka zabardast profit jump dikhaya hai, lekin ab sabki nazar **$11.75 billion** ki Organon acquisition aur debt par hai.
Tariff relief ki asal kahani
Sun Pharma ne US government ke saath ek deal sign ki hai jiske tehat unke innovative drug portfolio par Section 232 ke tariffs ko agle 2 saal ke liye taal diya gaya hai. Iske badle company ne US Medicaid programs ko 'Most Favoured Nation' pricing dene ka wada kiya hai. Halanki ye company ke liye ek badi jeet hai, lekin products ke daam kam karne se aage chalkar US market mein margins par thoda asar pad sakta hai.
Q1 FY27 ke solid numbers
Company ka focus ab pure tarah se 'specialty medicines' par hai, jo purane 'generics' business ki susti ko cover kar raha hai. Is quarter mein:
- Consolidated Net Profit: 27% YoY badhkar ₹2,895 Crore ho gaya hai.
- Revenue: 10.1% ki growth ke saath ₹151,836 million tak pahuncha.
- Innovation contribution: Total sales mein innovative medicines ka hissa ab 21.9% ho gaya hai.
Organon deal: Growth ya risk?
Market ab $11.75 billion ki Organon deal par focus kar raha hai. Ye deal 2027 ki shuruat mein complete hone ki umeed hai aur company ko biosimilars aur women’s health mein world leader bana sakti hai. Lekin dikkat ye hai ki company cash-rich status se hatkar debt ki taraf ja rahi hai, jahan Net Debt/EBITDA ratio lagbhag 2.3x tak pahunchne ka dar hai.
Iske alawa, LIB Therapeutics ke saath cholesterol medication ki licensing deal se company China aur US ke bahar bhi apne pair pasaar rahi hai. Generics market mein pricing pressure abhi bhi ek bada risk bana hua hai, jise manage karna management ke liye challenge hoga.